EN DE
Watch Chaoju Eye Care Holdings Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Chaoju Eye Care Holdings Ltd (2219) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Chaoju Eye Care Holdings Ltd stock HK$5.70, price HK$2.39, upside +138.5%, quality 62 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China · ISIN KYG2047K1094

CE Chaoju Eye Care Holdings Ltd logo Thin data Nov 14, 2026

Chaoju Eye Care Holdings Ltd

2219 · HK

Cheap (58% below fair value), solid company and rising price: meets all 3 rules.

Get notified free when this changes
Fair value HK$5.70 · Strongly undervalued 
Quality 62/100 
Rising price (uptrend) 
Solidly profitable · 12.0% net margin (TTM) 
Low debt 
Generates free cash flow 
9.1% dividend yield · Well covered
Ranks above peers (12/14) 
Even on cautious assumptions the value is 55% above the price (HK$3.70). 
Mixed Growth (revenue 5y +11.4 %/yr in CNY) 
Moderate moat 52/100 · thin data
Thin data 
Watch Chaoju Eye Care Holdings Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$12.18 HK$2.08 Fair Value HK$5.70 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range HK$2.08 – HK$12.18 · fair‑value band HK$3.70 – HK$8.18 · the HK$2.39 price screens below the HK$5.70 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow Chaoju Eye Care Holdings in your weekly email

Every Wednesday you see whether Chaoju Eye Care Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Chaoju Eye Care Holdings Limited, together with its subsidiaries, owns and operates a network of ophthalmic hospitals and centers in the People's Republic of China.

Show moreShow less

The company offers in-patient and out-patient ophthalmic medical services; and consumer ophthalmic services, including treatments and prevention for various ophthalmic disorders, such as refractive and presbyopia correction, and myopia prevention and control.

It also provides basic ophthalmic services for the treatment of a range of eye diseases, including cataract, glaucoma, squint, ocular fundus diseases, ocular surface diseases, orbital diseases, dry eye syndrome, and oculoplastic and pediatric eye diseases.

In addition, the company engages in investment management activities; and the sale of equipment, optical products, and medical consumables. Chaoju Eye Care Holdings Limited was founded in 1988 and is headquartered in Beijing, China.

Stock analysis

Chaoju Eye Care Holdings Ltd (2219) currently trades at HK$2.39, while our model-based Fair Value estimate is HK$5.70, implying the stock looks roughly 58% undervalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of HK$6.40 per share, and 23 of the 26 models we run sit above the HK$2.39 price.

Bear case: the Asset-Based group reads lowest at HK$1.76, and 3 of the 26 models stay below the price. Data coverage for this calculation is low.

Scenario range: HK$3.70 (bear) to HK$8.18 (bull), the price of HK$2.39 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 62/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Chaoju Eye Care Holdings Ltd reported revenue of 1.4B CNY in FY2025 versus 998M CNY in FY2021, a compound +8.1%/yr. Reported net income was 183M CNY in FY2025, compounding +3.2%/yr from FY2021.

Key figures

Market cap HK$1.7B (≈ $212M) Micro · P/E ratio 8.8 · P/S ratio 1.18 · Dividend yield 9.1% · Net margin 13.5% · Return on equity 6.8% · Return on assets (EBIT) 9.2% (5-year average) · Operating margin 17.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).

What moves the price

The share trades about 15% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at 139%, 2219 screens cheaper than that median.

Fair Value models

Bear HK$3.70 Fair Value HK$5.70 Bull HK$8.18
Price HK$2.39 · Upside +138.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF HK$2.69 HK$3.52 HK$4.63 82
Growth DCF HK$2.69 HK$3.40 HK$4.28 80
Owner Earnings HK$2.64 HK$3.46 HK$4.53 78
All 26 models by family
DCF Models
FCF DCF HK$2.69 HK$3.52 HK$4.63 82
Owner Earnings HK$2.64 HK$3.46 HK$4.53 78
5Y Revenue Exit HK$3.70 HK$5.69 HK$8.29 72
5Y EBITDA Exit HK$5.25 HK$8.64 HK$12.68 74
5Y P/E Exit HK$4.29 HK$6.82 HK$9.53 70
10Y Revenue Exit HK$3.14 HK$4.72 HK$6.91 66
10Y EBITDA Exit HK$4.11 HK$6.54 HK$9.91 67
10Y P/E Exit HK$3.57 HK$5.42 HK$7.76 64
Earnings-Based
Graham-Dodd HK$2.14 HK$7.25 HK$9.72 64
Lynch FV HK$2.47 HK$3.53 HK$4.59 61
PEG = 1.0 HK$2.47 HK$3.53 HK$4.59 57
EPV HK$2.94 HK$3.20 HK$3.43 74
Dividend Discount
Gordon GGM HK$1.14 HK$1.98 HK$2.63 68
DDM Multi-Stage HK$1.14 HK$1.81 HK$2.12 67
Multiples
P/E Multiple HK$5.19 HK$6.92 HK$8.65 63
P/S Multiple HK$4.01 HK$5.35 HK$6.69 58
P/B Multiple HK$3.63 HK$4.84 HK$6.05 55
EV/EBIT HK$5.77 HK$7.54 HK$9.30 66
EV/EBITDA HK$7.51 HK$9.85 HK$12.19 67
EV/Revenue HK$4.26 HK$5.88 HK$7.50 54
Asset-Based
NCAV (Graham) HK$1.16 HK$1.76 HK$2.20 54
Growth DCF
Growth DCF HK$2.69 HK$3.40 HK$4.28 80
Rev-Margin DCF HK$3.70 HK$5.66 HK$7.96 72
Economic Profit
Residual Income HK$3.14 HK$3.24 HK$3.52 76
ROIC Compounder HK$2.94 HK$3.20 HK$3.43 72
Growth Earnings
Growth-Adj P/E HK$4.40 HK$6.29 HK$8.17 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 62/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 41
How much profit the company makes from its sales and capital
Quality Growth 34
Are margins and returns getting better?
Cashflow 55
Do the profits arrive as real cash?
Financial strength 91
Debt, balance sheet and risk of trouble
Investment 64
Does it invest with discipline instead of growing at any price?
Low Volatility 87
How calm the share price moves, does not count
Price momentum 34
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 31
Distance to the 52-week high, does not count
New shares 84
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 83/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−3.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.4%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.6%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+16.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+7.8%
Dividend (yield on the price)9.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.23% → 18%

Growth Forecast

Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.

Watch 2219, get fair value alerts →

Compare Chaoju Eye Care Holdings Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 249 stocks

Beats the industry median on 12/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 62 · Above median
Fair Value upside +138.5% · Top 25%
Profitability
Return on equity (12 months) 6.8% · Below median
Return on assets 6.1% · Above median
Net margin (12 months) 12.0% · Top 25%
Operating margin (12 months) 17.1% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 1.8% · Below median
Dividend yield (12 months) 9.1% · Top 25%
Balance sheet
Debt / equity 0.02× · Lowest 25%

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/E (12 months) 8.8× · Cheapest 25%
P/B 0.59× · Cheapest 25%
P/S (12 months) 1.03× · Cheaper than median
Price / free cash flow (fiscal year) 12.5× · Cheaper than median
EV/EBITDA 3.0× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 34
FUTURE (revenue growth)9 · sector 31
PAST (return on equity)27 · sector 31
HEALTH (low debt)99 · sector 90
DIVIDEND (yield)100 · sector 38

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $22.03 $45.73 +108% vs 2219
DaVita Inc DVA $174.56 $218.90 +25% vs 2219
Aier Eye Hospital Group 300015 ¥8.84 ¥10.88 +23% vs 2219
HCA Healthcare, Inc HCA $499.05 $547.34 +10% vs 2219
Tenet Healthcare Corporation THC $286.03 $279.20 −2% vs 2219
The Ensign Group ENSG $188.41 $140.09 −26% vs 2219
Encompass Health Corporation EHC $140.99 $94.81 −33% vs 2219
Fresenius SE FRE €53.62 €34.77 −35% vs 2219
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,526 ₹5,234 −39% vs 2219
Dr. Sulaiman Al Habib Medical Services Group 4013 212.10 SAR 109.45 SAR −48% vs 2219

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Chaoju Eye Care Holdings Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Chaoju Eye Care Holdings Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2219

Frequently asked questions

Is Chaoju Eye Care Holdings Ltd (2219) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of HK$5.70 versus a price of HK$2.39, about +139% upside (undervalued).
What is the fair value of 2219?
Our model-based fair value for Chaoju Eye Care Holdings Ltd is HK$5.70 (as of Nov 14, 2026), built from audited fundamentals. The current price: HK$2.39.
What is the quality score of 2219?
Chaoju Eye Care Holdings Ltd has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Chaoju Eye Care Holdings Ltd (2219)?
Our model-based price target is the fair value of HK$5.70 (as of Nov 14, 2026) from 26 valuation models. Cautious scenario HK$3.70, optimistic scenario HK$8.18. It is a calculation from audited fundamentals, not an analyst target.
What is the Chaoju Eye Care Holdings Ltd stock forecast for 2026?
Our models put fair value at HK$5.70, about +139% upside versus a price of HK$2.39 (undervalued). Cautious scenario HK$3.70, optimistic scenario HK$8.18. The calculation is refreshed regularly with new filings.
What is the revenue of Chaoju Eye Care Holdings Ltd (2219)?
Chaoju Eye Care Holdings Ltd reported trailing-twelve-month revenue of about 1.4B CNY (latest available figure, as of Nov 14, 2026).
Does Chaoju Eye Care Holdings Ltd pay a dividend?
Chaoju Eye Care Holdings Ltd currently shows a dividend yield of 9.12% relative to its recent price (as of Nov 14, 2026).
How much is the dividend of Chaoju Eye Care Holdings Ltd (2219) and when is the ex-dividend date?
Chaoju Eye Care Holdings Ltd pays a dividend of HK$0.218 per share a year, a dividend yield of 9.1%. The last ex-dividend date was May 14, 2026. A dividend has been paid every year since at least 2022. The payout ratio is 41.4% of earnings. Free cash flow covers the dividend 1.48 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Chaoju Eye Care Holdings Ltd (2219)?
Today's price is already fair in a discounted-cash-flow model if free cash flow at Chaoju Eye Care Holdings Ltd shrinks by more than 40 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 11.4 % per year. As of Nov 14, 2026.
What discount rate (WACC) does the fair value of 2219 use?
Our models discount Chaoju Eye Care Holdings Ltd at 11.8 %: a base by market capitalisation (micro), damped by beta 0.54, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Chaoju Eye Care Holdings Ltd that is less than minus 40 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Chaoju Eye Care Holdings Ltd (2219) delivered so far?
Over the past 5 years revenue at Chaoju Eye Care Holdings Ltd grew 11.4 % a year. The price currently implies free-cash-flow growth of less than minus 40 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Chaoju Eye Care Holdings Ltd (2219) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Chaoju Eye Care Holdings Ltd (less than minus 40 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Chaoju Eye Care Holdings Ltd (2219)?
The free-cash-flow yield on the price is 7.98 %: that much free cash flow Chaoju Eye Care Holdings Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Chaoju Eye Care Holdings Ltd (2219)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Chaoju Eye Care Holdings Ltd it is HK$5.70 per share (as of Nov 14, 2026), against a price of HK$2.39. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Chaoju Eye Care Holdings Ltd stock overvalued or undervalued in 2026?
As of Nov 14, 2026, 2219 trades below its calculated fair value: price HK$2.39, fair value HK$5.70, a gap of about +139% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2219?
No. The price is what the market pays today (HK$2.39); the fair value is what the company's own numbers justify (HK$5.70). For Chaoju Eye Care Holdings Ltd the two are HK$3.31 per share apart. That gap is exactly why we show both numbers side by side.
How much is Chaoju Eye Care Holdings Ltd worth?
The market values Chaoju Eye Care Holdings Ltd at about HK$1.7B (market capitalisation, as of Nov 14, 2026). Per share that is HK$2.39; our models calculate a fair value of HK$5.70 per share.
What do the bullish and bearish scenarios say about 2219?
Our models span a range for Chaoju Eye Care Holdings Ltd: cautious scenario HK$3.70, base HK$5.70, optimistic HK$8.18 per share (as of Nov 14, 2026, price HK$2.39). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 2219?
Chaoju Eye Care Holdings Ltd trades at a price-to-earnings ratio of 8.8 (as of Nov 14, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$5.70 is built from several models across several years. Other multiples: P/B 0.6, P/S 1.0, EV/EBITDA 3.0.
How solid is the balance sheet of Chaoju Eye Care Holdings Ltd (2219)?
Balance-sheet figures for Chaoju Eye Care Holdings Ltd (as of Nov 14, 2026): return on equity 6.8%, debt of 0.02 per unit of equity. They feed the Quality Score of 62/100, which measures business quality independently of the share price.
How far is 2219 from its 52-week high?
Chaoju Eye Care Holdings Ltd trades at HK$2.39, about 15% below its 52-week high of HK$2.81 and 6% above the low of HK$2.26 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$5.70 is for.
Which stocks are comparable to Chaoju Eye Care Holdings Ltd?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Chaoju Eye Care Holdings Ltd stock attractive at the current price?
The data as of Nov 14, 2026: price HK$2.39, calculated fair value HK$5.70 (+139%), Quality Score 62/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2219 calculated?
We run Chaoju Eye Care Holdings Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$5.70 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Chaoju Eye Care Holdings Ltd currently trades 58% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Chaoju Eye Care Holdings Ltd (2219)?
The closing price on Nov 13, 2026 was HK$2.39. Our model-based fair value is HK$5.70, about +139% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Chaoju Eye Care Holdings Ltd right now?
The price is below even our cautious bear case (HK$3.70). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (62/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (HK$3.70 to HK$8.18) leaves room in how you read the outcome.

Key figures of Chaoju Eye Care Holdings Ltd

How large is the market capitalisation of Chaoju Eye Care Holdings Ltd (2219)?
The market capitalisation of Chaoju Eye Care Holdings Ltd is HK$1.7B (≈ $212M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Chaoju Eye Care Holdings Ltd (2219)?
The price-to-sales ratio of Chaoju Eye Care Holdings Ltd is 1.18 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Chaoju Eye Care Holdings Ltd (2219)?
The dividend yield of Chaoju Eye Care Holdings Ltd is 9.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Chaoju Eye Care Holdings Ltd (2219)?
The net margin of Chaoju Eye Care Holdings Ltd is 13.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Chaoju Eye Care Holdings Ltd (2219)?
The return on equity (ROE) of Chaoju Eye Care Holdings Ltd is 6.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Chaoju Eye Care Holdings Ltd (2219)?
On an EBIT basis the return on assets of Chaoju Eye Care Holdings Ltd is 9.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Chaoju Eye Care Holdings Ltd (2219)?
The operating margin of Chaoju Eye Care Holdings Ltd is 17.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Chaoju Eye Care Holdings Ltd (2219)?
Revenue at Chaoju Eye Care Holdings Ltd is growing 1.8% versus a year earlier (3y avg +11.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Chaoju Eye Care Holdings Ltd (2219)?
Earnings per share at Chaoju Eye Care Holdings Ltd are down 14.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Chaoju Eye Care Holdings Ltd (2219) hold?
Chaoju Eye Care Holdings Ltd holds more cash than debt, 279M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Chaoju Eye Care Holdings Ltd in the live analysis

One click puts Chaoju Eye Care Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.